Barclays analyst Carter Gould lowered the firm’s price target on Biogen to $307 from $310 and keeps an Equal Weight rating on the shares. The analyst sees "challenging setups" for the U.S. biopharmaceutical space in Q1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Truist biotechnology analyst to hold an analyst/industry conference call
- Drugmakers call for abortion pill ruling reversal, Reuters reports
- FDA AdCom to convene on June 9th to discuss Biogen/Eisai’s LEQEMBI in AD
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data
- Biogen appoints Keeney as Head of Corporate Development